Literature DB >> 8130097

Therapeutics of X-linked hypophosphatemic rickets.

K Latta1, S Hisano, J C Chan.   

Abstract

X-linked hypophosphatemia, the most common form of familial rickets, is conventionally treated with 1,25-dihydroxyvitamin D3 (5-50 ng/kg per day) plus phosphate supplementation (70-100 mg/kg per day). However, nephrocalcinosis is noted in many children treated with this therapy. Whether to treat or not and whether such treatment should be continued into adulthood or in pregnancy are unsettled questions. This article reviews these controversies and provides current recommendations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8130097     DOI: 10.1007/bf01213343

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  33 in total

1.  Nephrocalcinosis and its relationship to treatment of hereditary rickets.

Authors:  P R Goodyer; J B Kronick; S Jequier; T M Reade; C R Scriver
Journal:  J Pediatr       Date:  1987-11       Impact factor: 4.406

2.  Micromorphologic features of dentin in vitamin D-resistant rickets: correlation with clinical grading of severity.

Authors:  W K Seow; K Romaniuk; S Sclavos
Journal:  Pediatr Dent       Date:  1989-09       Impact factor: 1.874

3.  Hypophosphatemic vitamin D-resistant rickets: metabolic balance studies in a child receiving 1,25 dihydroxyvitamin D3, phosphate, and ascorbic acid.

Authors:  G H Hirschman; H F DeLuca; J C Chan
Journal:  Pediatrics       Date:  1978-03       Impact factor: 7.124

4.  X-linked hypophosphataemic rickets: Inadequate therapeutic response to 1,25-dihydroxycholecalciferol.

Authors:  F H Glorieux; M F Holick; C R Scriver; H F DeLuca
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

5.  Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3.

Authors:  J C Chan; R D Lovinger; P Mamunes
Journal:  Pediatrics       Date:  1980-09       Impact factor: 7.124

6.  Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets.

Authors:  F H Glorieux; P J Marie; J M Pettifor; E E Delvin
Journal:  N Engl J Med       Date:  1980-10-30       Impact factor: 91.245

7.  Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.

Authors:  R M Harrell; K W Lyles; J M Harrelson; N E Friedman; M K Drezner
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

8.  Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets.

Authors:  G S Reusz; K Latta; P F Hoyer; D J Byrd; J H Ehrich; J Brodehl
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

9.  Effects of hydrochlorothiazide and amiloride in renal hypophosphatemic rickets.

Authors:  U Alon; J C Chan
Journal:  Pediatrics       Date:  1985-04       Impact factor: 7.124

10.  Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1 alpha-hydroxyvitamin D3.

Authors:  H Rasmussen; M Pechet; C Anast; A Mazur; J Gertner; A E Broadus
Journal:  J Pediatr       Date:  1981-07       Impact factor: 4.406

View more
  2 in total

1.  Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism.

Authors:  Uri S Alon; Roshanak Monzavi; Marc Lilien; Majid Rasoulpour; Mitchell E Geffner; Ora Yadin
Journal:  Pediatr Nephrol       Date:  2003-01-18       Impact factor: 3.714

Review 2.  The enigma of hyperparathyroidism in hypophosphatemic rickets.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Pediatr Nephrol       Date:  2004-03-11       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.